---
title: "AgomAb Therapeutics NV (AGMB.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/AGMB.US.md"
symbol: "AGMB.US"
name: "AgomAb Therapeutics NV"
industry: "Pharmaceuticals"
---

# AgomAb Therapeutics NV (AGMB.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [agomab.com](https://agomab.com) |

## Company Profile

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gast...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.67 | 181/257 | - | - | - |
| PB | -6.73 | 215/257 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/AGMB.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/AGMB.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/AGMB.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.